|
Feb 23
|
Novartis AG (NVS): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
|
|
Feb 20
|
Novartis AG (NVS): Among the Best Global Stocks to Buy According to Hedge Funds
|
|
Feb 20
|
BMO Expands Canadian Depositary Receipt (CDR) Lineup with 10 New Listings from Europe and Japan
|
|
Feb 18
|
HMRI and Novartis Australia sign MoU to expedite medical research
|
|
Feb 14
|
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
|
|
Feb 14
|
Is Novartis AG (NVS) the Best Foreign Dividend Stock to Buy According to Analysts?
|
|
Feb 14
|
Health Canada approves Novartis’ Fabhalta for PNH with haemolytic anaemia
|
|
Jan 17
|
Sector Update: Health Care Stocks Rise Premarket Friday
|
|
Jan 16
|
US appeals court reinstates pause on generic version of Novartis' Entresto
|
|
Jan 16
|
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
|
|
Jan 16
|
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson
|
|
Jan 16
|
Novartis wins temporary pause to Entresto generic launch in US
|
|
Jan 14
|
JP Morgan 2025: Novartis streamlines its portfolio to drive future growth
|
|
Jan 3
|
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
|
|
Jan 3
|
Positive data could expand use of Novartis’ gene therapy for SMA
|
|
Dec 31
|
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
|
|
Dec 31
|
Here's Why Novartis (NVS) is a Strong Growth Stock
|
|
Dec 31
|
Novartis’ Gene Therapy Shows Promise in Treating SMA
|
|
Dec 31
|
Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint
|
|
Dec 30
|
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
|